Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com -- Carl Zeiss Meditec AG reported strong second-quarter results, beating expectations for revenue, EBITA, and EPS, sending its shares up by over 3% on Tuesday.
The healthcare company posted revenues of €560 million, a 9.2% increase over analyst estimates, with 7% organic growth (19% reported). EBITA came in at €78 million, up 42% from consensus, reflecting a margin of 13.9%. EPS reached €0.52, a 58% increase compared to expectations.
The outperformance was largely driven by stronger-than-expected results in China’s refractive business.
The recovery, particularly the shift toward higher-margin SMILE procedures over LASIK, provided a boost.
This marks a reversal from earlier periods when weakness in China had hindered the company’s performance.
Analysts at RBC Capital Markets view this recovery as a positive sign, suggesting it could lead to upside in FY2025 forecasts, although the full extent of the recovery remains to be seen.
Despite the strong Q2, Carl Zeiss Meditec maintained its FY2025 guidance, citing macroeconomic and geopolitical risks, including potential U.S. tariffs and currency volatility.
The company continues to forecast "moderate revenue growth" and "stable to slightly higher EBITA."
Consensus estimates for FY2025 project revenue of €2.19 billion (6% growth) and EBITA of €276.2 million, up from €246 million in FY2024.
While the Q2 results are reassuring, analysts remain cautious, awaiting further confirmation of the China recovery and clarity on the impact of external risks.